|
KMID : 1200020120360040262
|
|
Diabetes & Metabolism Journal
2012 Volume.36 No. 4 p.262 ~ p.267
|
|
|
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
|
|
Lee Jin-Mi
Hong Seok-Woo
Rhee Eun-Jung
Lee Won-Young
|
|
|
Abstract
|
|
|
|
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
|
|
|
KEYWORD
|
|
|
Fatty acid oxidation, Glucagon-like peptide 1, Non-alcoholic fatty liver disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|